PHOENIX, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire Stock Day Podcast features Medifocus, Inc. (OTCQB: MDFZF and
TSXV: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical technologies that utilize patented
Focal Microwave Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. William Jow, M.D.,
President, CEO of Medifocus, talked with host Mr. Everett Jolly.
Dr. Jow began the interview by explaining, “I am also a practicing urologist who has always been interested in minimally
invasive treatments for the enlarged prostate, or BPH, and prostate cancer. After having practiced medicine for over 30 years, I’m
fully aware of the potential side effects of medications and surgeries, therefore I am always looking for the best possible
treatment options for my patients; that’s how I initially got involved with Medifocus, first as an end user of
Prolieve®, then Medical Director, and now CEO,” explained Dr. Jow.
Dr. Jow went on to say after he saw how his patients improved after being treated with Prolieve®, he is convinced it
is one of the best and safest treatment options for most men with symptomatic BPH.
“Recently the FDA has approved our 5-year follow up study which confirms the safety, efficacy, and very positive long-term
durable outcome of Prolieve®. The certified and independently conducted FDA Post Market Study clearly demonstrated
improvement of voiding symptoms, urinary flow rate and quality of life,” Dr. Jow commented.
Dr. Jow added that it is an important milestone that these findings have been approved by the FDA because now Medifocus can
levege the positive clinical findings to promote Prolieve®. Mr. Jolly then asked what makes Prolieve®
different from other products on the markets and asked to be walked through the treatment.
“Prolieve® is the only Transurethral Thermodilatation™ (TUTD™) device on the market now,” Dr. Jow explained. He also
said it comes with a patented dilating balloon combination that enables it to deliver lower energy thermotherapy and provides
immediate symptomatic relief with a safety profile that exceeds any competitors. Dr. Jow also added, “The patient does not feel the
discomfort associated with high energy treatments.”
Dr. Jow went on to explain Medifocus is currently exploring the opportunity of using Prolieve® in focal therapy for prostate
cancer. He said he hopes they can help a large percentage of those with prostate cancer avoid surgery and radiation and their side
effects.
“Right after our first interview with you, about a month ago, we submitted a new patent application for a new innovated
Microwave Cluster Tissue Ablation technology to the U.S. patent office adding to our already large portfolio of patents,” said Dr.
Jow.
Mr. Jolly then asked about the Company's plans for Breast Cancer treatment. Dr. Jow said they are working with the FDA on APA
1000, and the new patent they submitted will also help with the breast cancer treatment. To date, Phase I and II clinical trials
have been completed with positive outcomes; Phase III has been approved by the FDA and awaits funding to start.
“Our innovative approach will likely enhance the efficacy and reduce the systemic side effects of immunotherapy and chemotherapy
agents. It’s certainly very exciting,” said Dr. Jow.
Dr. Jow then explained that Medifocus is a small company that has become self-sustainable through its revenue generating
Prolieve® operation. He says they have assembled an excellent staff that constantly adds value to the company through
research and development.
“I’m confident we can bring the best-in-class, minimally invasive treatment options to our patients through our passion and
clinical experience,” said Dr. Jow.
To listen to the entire interview with Dr. Jow, follow this link: https://upticknewswire.com/featured-interview-ceo-dr-william-jow-of-medifocus-inc-otcqb-mdfzf/
About the Prolieve® Thermodilatation™ System
The Prolieve® Thermodilatation™ System offers potential relief to the millions of men who suffer from
Benign Prostatic Hyperplasia (BPH), a condition that becomes common as men age. About half of men over 50 have some enlargement of
the prostate gland, and this rises to about 90% among those over 70. As the prostate enlarges, it constricts the urethra, thereby
restricting the passage of urine. Persistent restriction and further progression of BPH, if left untreated, often results in
worsening of lower urinary tract symptoms (LUTS). Further complications of this process may result in urinary retention, bladder
stones and infection, as well as compromised bladder and kidney function.
The Prolieve® System is a novel focused heat therapy which utilizes a unique combination of focused
heat energy directed at the prostate in combination with a patented, water cooled and pressurized dilatation balloon to achieve
immediate and long-term relief of BPH symptoms with very minimal treatment related side effects after a brief in-office procedure
performed under local anesthesia. The unique advantage of this combined "heat plus compression" therapy is twofold: first, the heat
denatures local tissue proteins of the (balloon) dilated urethra, resulting in an expanded and stiffened urethral lumen functioning
as a biological stent. Second, the compression reduces local blood flow thus increasing the thermal efficiency of the microwave
energy to achieve apoptosis and tissue ablation in the targeted prostate gland. As the transurethral microwave energy is applied to
the entire prostate, a computerized feedback system involving the rectal temperature probe renders the rectal temperature not to
exceed 41-42 ?C, thus ensuring safety of the rectal wall and neurovascular bundles essential to preservation of erectile
function.
About Medifocus, Inc.:
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a Biotechnology Company with a portfolio of medical technologies that
utilize patented Focal Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. Its
Prolieve® Thermodilatation™ System offers symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) through a
simple, fast, in-office treatment. Prolieve® is both FDA and Medicare approved for treating symptomatic BPH with over 100,000 cases
performed in the U.S. alone, and with proven long-term safety, efficacy and durability. Its APA 1000 Breast Cancer Treatment System
was licensed from Massachusetts Institute of Technology and developed by the Medifocus team. The Targeted Focal Thermotherapy has
been demonstrated in Phase 2 clinical trials to offer significantly better tumor shrinkage in patients treated with the combined
Chemothermal therapy compared those treated with Chemotherapy alone. APA 1000 was also shown to be effective in reducing margin
positivity among patients treated with such thermotherapy prior to lumpectomy.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more details, please visit:
www.medifocusinc.com
www.prolieve.com
www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
Company Relations: Medifocus, Inc. Tel: 410-290-5734 Email to info@medifocusinc.com
Forward-Looking Statements
This news release contains “forward-looking statements” and “forward-looking information”, which may not be based on historical
facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with
respect to the benefit to Medifocus’ future growth resulting from the acquisition of additional intellectual property rights,
additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking
statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate”, “estimate”
and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are
based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and
forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results
events or developments to be materially different from any future results, events or developments expressed or implied by such
forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned
not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable
securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any
revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results,
events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors
while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued,
under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both
national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio
show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its
Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the
company’s message board at https://investorshangout.com/
SOURCE:
Uptick Newswire
602-441-3474
https://upticknewswire.com/
